glp-1 shortage us FDA restricts non-approved compounded weight loss products Ozempic and Wegovy removed from

Some ingredients in GLP-1 patches may act as stimulants and could raise blood pressure or interact with other medications

Higher doses tend to provide the greatest weight loss and metabolic improvements, but are also associated with an increased likelihood and intensity of gastrointestinal symptoms

But the way telemedicine is practiced varies widely, and state laws largely dictate rules that telehealth providers must follow

Brands like Ozempic and Wegovy are a semaglutide (GLP-1 RA)

Microdosing GLP-1 lacks clinical trial evidence and regulatory approval, making its safety profile unknown

However, a significant decrease in insulinotropic activity was observed with GIP in diabetic patient with hyperglycemia, whereas relatively preserved activity was noted with GLP-1 in the same patients (58), suggesting divergent effects of GIP and GLP-1 on -cells ( Figure 1 Section B)